Published in PLoS One on July 23, 2010
Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT. Oncogene (2012) 1.13
Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene (2012) 1.02
Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression. Cancer Res (2013) 1.02
Cytoplasmic retention of protein tyrosine kinase 6 promotes growth of prostate tumor cells. Cell Cycle (2010) 0.95
Protein-tyrosine kinase 6 promotes peripheral adhesion complex formation and cell migration by phosphorylating p130 CRK-associated substrate. J Biol Chem (2011) 0.94
PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer. Cancer Res (2013) 0.92
Disruption of the mouse protein tyrosine kinase 6 gene prevents STAT3 activation and confers resistance to azoxymethane. Gastroenterology (2011) 0.90
Protein-tyrosine phosphatase 1B antagonized signaling by insulin-like growth factor-1 receptor and kinase BRK/PTK6 in ovarian cancer cells. J Biol Chem (2013) 0.88
Context-specific protein tyrosine kinase 6 (PTK6) signalling in prostate cancer. Eur J Clin Invest (2013) 0.86
The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of β-catenin. PLoS One (2011) 0.86
RSK promotes prostate cancer progression in bone through ING3, CKAP2, and PTK6-mediated cell survival. Mol Cancer Res (2014) 0.85
Protein tyrosine kinase 6 regulates mammary gland tumorigenesis in mouse models. Oncogenesis (2013) 0.85
PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors. Oncotarget (2014) 0.84
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim. Breast Cancer Res (2015) 0.83
PTK6 promotes cancer migration and invasion in pancreatic cancer cells dependent on ERK signaling. PLoS One (2014) 0.83
p90 RSK2 mediates antianoikis signals by both transcription-dependent and -independent mechanisms. Mol Cell Biol (2013) 0.82
Targeting protein tyrosine kinase 6 enhances apoptosis of colon cancer cells following DNA damage. Mol Cancer Ther (2012) 0.80
HIF-1α-independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion. Cancer Biol Ther (2014) 0.79
Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse. Cell Death Dis (2015) 0.78
Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition. Biochemistry (2015) 0.77
Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy. World J Clin Oncol (2014) 0.77
Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer. Cancer Res (2016) 0.76
Insulin-like growth factors are essential to prevent anoikis in oestrogen-responsive breast cancer cells: importance of the type I IGF receptor and PI3-kinase/Akt pathway. Mol Cancer (2016) 0.76
The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR. Biochem Pharmacol (2016) 0.75
PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells. Breast Cancer Res (2016) 0.75
PTK6 promotes hepatocellular carcinoma cell proliferation and invasion. Am J Transl Res (2016) 0.75
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods (2003) 18.51
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell (2002) 7.35
Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature (2009) 5.32
Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ (2009) 5.28
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol (2005) 5.00
Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature (2004) 4.53
Induction of autophagy during extracellular matrix detachment promotes cell survival. Mol Biol Cell (2007) 3.37
Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol (2008) 2.96
Anoikis resistance and tumor metastasis. Cancer Lett (2008) 2.90
Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat (2007) 2.49
Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res (2008) 2.37
Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin. Mol Cell Biol (2004) 1.88
Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res (2008) 1.82
BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene (1997) 1.77
The paradox of autophagy and its implication in cancer etiology and therapy. Apoptosis (2009) 1.77
Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. Cancer Res (2007) 1.75
Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene (1994) 1.75
Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res (2009) 1.75
BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat (2005) 1.73
The IGF-I receptor in cancer research. Exp Cell Res (1999) 1.64
Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor. J Biol Chem (1996) 1.56
Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells. Oncogene (2003) 1.49
Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. Oncogene (2000) 1.48
Brk, Srm, Frk, and Src42A form a distinct family of intracellular Src-like tyrosine kinases. Oncol Res (2003) 1.45
Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proc Natl Acad Sci U S A (2009) 1.45
Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc Natl Acad Sci U S A (2008) 1.36
PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer (2007) 1.34
Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK. Biochim Biophys Acta (2010) 1.32
Simultaneous over-expression of the Her2/neu and PTK6 tyrosine kinases in archival invasive ductal breast carcinomas. J Pathol (2005) 1.30
Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6. Breast Cancer Res (2007) 1.27
The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. Cancer Biol Ther (2006) 1.26
Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer (1992) 1.26
The intracellular tyrosine kinase Brk sensitizes non-transformed cells to inducers of apoptosis. Cell Cycle (2005) 1.18
Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. Cancer Res (2009) 1.18
Src phosphorylates the insulin-like growth factor type I receptor on the autophosphorylation sites. Requirement for transformation by src. J Biol Chem (1996) 1.18
A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene (2004) 1.11
Anti-apoptotic signaling of the IGF-I receptor in fibroblasts following loss of matrix adhesion. Oncogene (1999) 1.10
The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol (2006) 1.10
Induction of protein tyrosine kinase 6 in mouse intestinal crypt epithelial cells promotes DNA damage-induced apoptosis. Gastroenterology (2009) 1.10
Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage. Am J Pathol (2009) 1.10
Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients. Br J Cancer (2008) 1.09
Interaction between Brk kinase and insulin receptor substrate-4. Oncogene (2005) 1.06
A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis. Cancer Res (2007) 1.02
Oncogenic functions of PTK6 are enhanced by its targeting to plasma membrane but abolished by its targeting to nucleus. J Biochem (2009) 1.02
IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors (2007) 0.99
BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells. Clin Cancer Res (2009) 0.97
The insulin-like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer. Genes Chromosomes Cancer (1994) 0.91
Overexpression of PTK6 (breast tumor kinase) protein--a prognostic factor for long-term breast cancer survival--is not due to gene amplification. Virchows Arch (2009) 0.87
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Mapping and analysis of chromatin state dynamics in nine human cell types. Nature (2011) 24.37
Signatures of mutational processes in human cancer. Nature (2013) 21.63
International network of cancer genome projects. Nature (2010) 20.35
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods (2003) 18.51
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
The life history of 21 breast cancers. Cell (2012) 10.59
Regulation of cellular metabolism by protein lysine acetylation. Science (2010) 10.55
Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol (2010) 9.24
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer (2005) 8.70
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A (2006) 8.01
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell (2002) 7.35
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature (2010) 7.05
Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications. Nat Biotechnol (2010) 7.00
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell (2012) 6.80
Ductal carcinoma in situ of the breast. N Engl J Med (2004) 6.63
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol (2007) 6.22
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 6.15
Acetylation of metabolic enzymes coordinates carbon source utilization and metabolic flux. Science (2010) 6.04
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Tumor heterogeneity: causes and consequences. Biochim Biophys Acta (2009) 5.90
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A (2011) 5.53
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 5.52
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment. Nature (2009) 5.32
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Mesenchyme Forkhead 1 (FOXC2) plays a key role in metastasis and is associated with aggressive basal-like breast cancers. Proc Natl Acad Sci U S A (2007) 5.24
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol (2005) 5.00
A public genome-scale lentiviral expression library of human ORFs. Nat Methods (2011) 4.98
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96
Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell (2011) 4.79
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods (2009) 4.76
Mutant p53 drives invasion by promoting integrin recycling. Cell (2009) 4.75
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71